Semaglutide for weight loss costs anywhere from about $200 per month to over $1,000 per month, depending on whether you get the brand-name drug, a compounded version, or qualify for insurance coverage or savings programs. The list price for Wegovy, the FDA-approved semaglutide injection for weight loss, sits around $1,000 or more per month. But very few people actually pay that amount. Most land somewhere between $25 and $500 depending on their coverage and how they access the medication.
Brand-Name Wegovy Pricing
Wegovy is the only semaglutide product specifically approved for weight management. Its list price is roughly $1,000 per month, but Novo Nordisk now offers direct pricing options that bypass insurance entirely. Through the company’s program, you can get the two lowest doses (0.25 mg and 0.5 mg) for $199 per month for the first two months. After that, or for higher doses, the price rises to $349 per month.
If you have commercial insurance that covers Wegovy, you may be able to use the manufacturer’s savings card to bring your cost down to $25 per month for a 28-day supply. That’s a significant discount, but it only works with qualifying commercial plans. Medicare, Medicaid, and some government insurance programs don’t qualify for the savings card.
Novo Nordisk has also released a pill form of Wegovy. The oral version is priced at $149 per month for the lower doses through April 2026, then $199 per month for the maintenance dose after that.
What Insurance Typically Requires
Coverage for Wegovy is not automatic, even with good insurance. Most commercial health plans follow criteria that mirror the drug’s FDA labeling: a BMI above 30, or a BMI above 27 with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Beyond the BMI threshold, many plans add extra hurdles. About half of the major commercial plans studied by researchers at Tufts Medical Center required patients to already be following a reduced-calorie diet and exercise program. Several required enrollment in a formal behavioral modification program before they would approve the prescription.
Staying on the medication long-term also has conditions. Every plan that reported continuation criteria required documented weight loss of at least 4% to 5% from your starting weight to keep covering refills. If you don’t hit that benchmark, your plan could stop paying.
Compounded Semaglutide
Compounded semaglutide is a version made by specialty pharmacies rather than Novo Nordisk. It typically costs $200 to $500 per month without insurance. The exact price depends on the dose, whether the pharmacy adds other ingredients like vitamin B12, and the type of packaging (pre-filled syringes tend to cost more than vials you draw from yourself).
Many people access compounded semaglutide through telehealth platforms, which often bundle the medication with a monthly membership fee. Those fees vary widely. Some platforms charge nothing beyond the medication cost, while others charge $74 to $149 per month on top of the drug price. A platform charging $149 per month in membership fees plus $300 for the medication puts your real monthly cost closer to $450. When comparing options, make sure you’re adding the membership fee to the medication cost to get the true number.
One important note: compounded semaglutide exists in a regulatory gray area and its long-term availability depends on FDA enforcement decisions that can shift. It is not FDA-approved and does not go through the same manufacturing oversight as Wegovy.
The Dosing Schedule Affects Early Costs
Semaglutide is not a single flat dose from day one. You start at a very low dose and gradually increase over about four months. The standard schedule begins at 0.25 mg per week for the first four weeks, then steps up to 0.5 mg, then 1 mg, then 1.7 mg, before reaching the full maintenance dose of 2.4 mg at week 17 or later.
This matters for cost because the lower-dose introductory period is sometimes priced differently. Novo Nordisk’s direct pricing, for example, offers $199 per month only for those first two dose levels. Once you move to higher doses, you pay $349. If you’re budgeting for this medication, plan for the higher price as your ongoing cost, since you’ll spend most of your time at the maintenance dose.
If you experience side effects during the ramp-up (nausea is the most common), your doctor may delay a dose increase by four weeks, which can extend the time you spend at a lower, potentially cheaper dose.
What You Get for the Cost
In clinical trials, people taking the 2.4 mg maintenance dose of semaglutide lost an average of about 14% of their body weight over 52 weeks, compared to roughly 3% with a placebo. For someone who weighs 220 pounds, that translates to losing around 30 pounds in a year. Results vary, and some people lose significantly more or less than the average.
The weight loss is not permanent if you stop the medication. Most studies show that people regain a substantial portion of lost weight after discontinuing semaglutide, which means the monthly cost is ongoing for as long as you want to maintain the results. Over a year at $349 per month (Novo Nordisk’s direct price for maintenance doses), that’s roughly $4,200. At $25 per month with a savings card and commercial insurance, it’s $300 per year. The gap between those two figures is enormous, and which one applies to you depends almost entirely on your insurance situation.
When Generic Versions May Arrive
Novo Nordisk’s U.S. patent on semaglutide is set to expire in 2032. In October 2024, the company reached settlements with several major generic manufacturers, including Mylan (now Viatris), Sun Pharmaceutical, and Dr. Reddy’s Laboratories. The specific terms are confidential, but these settlements likely include agreed-upon dates for generic entry and possible royalty arrangements. Generic versions could arrive before 2032 depending on those terms, but no generic semaglutide is available in the U.S. today.
Outside the U.S., the timeline is faster. Semaglutide’s patent in China expires in 2026, and at least 15 Chinese pharmaceutical companies are developing generic versions, with 11 in final-stage clinical trials. These international generics won’t be available in the U.S. without separate FDA approval, but they signal that lower-cost options are on the horizon globally.